- Home
- MGF vs IVA Comparison
MGF vs IVA Comparison
Compare MGF & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGF
- IVA
- Stock Information
- Founded
- MGF 1987
- IVA 2011
- Country
- MGF United States
- IVA France
- Employees
- MGF N/A
- IVA N/A
- Industry
- MGF Trusts Except Educational Religious and Charitable
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- MGF Finance
- IVA Health Care
- Exchange
- MGF Nasdaq
- IVA Nasdaq
- Market Cap
- MGF 99.7M
- IVA 117.3M
- IPO Year
- MGF N/A
- IVA 2020
- Fundamental
- Price
- MGF $3.06
- IVA $2.17
- Analyst Decision
- MGF
- IVA Strong Buy
- Analyst Count
- MGF 0
- IVA 4
- Target Price
- MGF N/A
- IVA $13.25
- AVG Volume (30 Days)
- MGF 104.4K
- IVA 6.4K
- Earning Date
- MGF 01-01-0001
- IVA 09-25-2024
- Dividend Yield
- MGF 7.64%
- IVA N/A
- EPS Growth
- MGF N/A
- IVA N/A
- EPS
- MGF N/A
- IVA N/A
- Revenue
- MGF N/A
- IVA $20,652,523.00
- Revenue This Year
- MGF N/A
- IVA N/A
- Revenue Next Year
- MGF N/A
- IVA $361.78
- P/E Ratio
- MGF N/A
- IVA N/A
- Revenue Growth
- MGF N/A
- IVA N/A
- 52 Week Low
- MGF $2.91
- IVA $1.53
- 52 Week High
- MGF $3.46
- IVA $4.50
- Technical
- Relative Strength Index (RSI)
- MGF 43.74
- IVA 39.56
- Support Level
- MGF $2.95
- IVA $2.11
- Resistance Level
- MGF $3.09
- IVA $2.24
- Average True Range (ATR)
- MGF 0.04
- IVA 0.07
- MACD
- MGF -0.00
- IVA 0.01
- Stochastic Oscillator
- MGF 61.11
- IVA 26.58
About MGF MFS Government Markets Income Trust
MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.